KR20200040764A - 1,8-나프티리디논 화합물 및 그의 용도 - Google Patents
1,8-나프티리디논 화합물 및 그의 용도 Download PDFInfo
- Publication number
- KR20200040764A KR20200040764A KR1020207004250A KR20207004250A KR20200040764A KR 20200040764 A KR20200040764 A KR 20200040764A KR 1020207004250 A KR1020207004250 A KR 1020207004250A KR 20207004250 A KR20207004250 A KR 20207004250A KR 20200040764 A KR20200040764 A KR 20200040764A
- Authority
- KR
- South Korea
- Prior art keywords
- alkylene
- halogen
- alkyl
- compound
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Bc1nc(N(*)C(*)CC(*)C2*)c2c(*)c1* Chemical compound Bc1nc(N(*)C(*)CC(*)C2*)c2c(*)c1* 0.000 description 35
- ROZZTFNAIYMQEK-UHFFFAOYSA-N CC(CC1)CC2C1NCCC2 Chemical compound CC(CC1)CC2C1NCCC2 ROZZTFNAIYMQEK-UHFFFAOYSA-N 0.000 description 2
- IVKILQAPNDCUNJ-UHFFFAOYSA-N Cc1ccc2nc[s]c2c1 Chemical compound Cc1ccc2nc[s]c2c1 IVKILQAPNDCUNJ-UHFFFAOYSA-N 0.000 description 2
- OSRARURJYPOUOV-UHFFFAOYSA-N Cc1ccc2nccnc2c1 Chemical compound Cc1ccc2nccnc2c1 OSRARURJYPOUOV-UHFFFAOYSA-N 0.000 description 2
- VFTDYERUQVBMLH-UHFFFAOYSA-N Cc1nc(cccn2)c2[o]1 Chemical compound Cc1nc(cccn2)c2[o]1 VFTDYERUQVBMLH-UHFFFAOYSA-N 0.000 description 2
- NVXPSQIYZCKHMN-UHFFFAOYSA-N Cc1nc(cccn2)c2[s]1 Chemical compound Cc1nc(cccn2)c2[s]1 NVXPSQIYZCKHMN-UHFFFAOYSA-N 0.000 description 2
- ACPSWBYBOQDJIM-HAVVHWLPSA-N C/C(/C1=CC=C2N=CC=CC2C1)=C(/C1=CC=CCC1)\N=C(/C(C#C1)=C)\NC1=O Chemical compound C/C(/C1=CC=C2N=CC=CC2C1)=C(/C1=CC=CCC1)\N=C(/C(C#C1)=C)\NC1=O ACPSWBYBOQDJIM-HAVVHWLPSA-N 0.000 description 1
- ILBIJOWSHVGZPU-UHFFFAOYSA-N CC(C)c1ccc(cncc2)c2c1 Chemical compound CC(C)c1ccc(cncc2)c2c1 ILBIJOWSHVGZPU-UHFFFAOYSA-N 0.000 description 1
- ZHVYFXHRQMJDHD-UHFFFAOYSA-N CC(N1)=NC2C1NCCC2 Chemical compound CC(N1)=NC2C1NCCC2 ZHVYFXHRQMJDHD-UHFFFAOYSA-N 0.000 description 1
- UQKZBCCTHZAOJP-UHFFFAOYSA-N CC(NC1)=Nc2c1nccc2 Chemical compound CC(NC1)=Nc2c1nccc2 UQKZBCCTHZAOJP-UHFFFAOYSA-N 0.000 description 1
- AJQVUSINKLKYBG-UHFFFAOYSA-N CC1=CC(CCC=N2)C2N=C1 Chemical compound CC1=CC(CCC=N2)C2N=C1 AJQVUSINKLKYBG-UHFFFAOYSA-N 0.000 description 1
- RCKWIEUIVJOYJT-UHFFFAOYSA-N CC1C=NC=CC1 Chemical compound CC1C=NC=CC1 RCKWIEUIVJOYJT-UHFFFAOYSA-N 0.000 description 1
- HBIOHVIXJZTCHS-UHFFFAOYSA-N CC1CC2NC=NC2CC1 Chemical compound CC1CC2NC=NC2CC1 HBIOHVIXJZTCHS-UHFFFAOYSA-N 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- BDOVHCBMDRHNNW-UHFFFAOYSA-N CC1NN(C)C=C1 Chemical compound CC1NN(C)C=C1 BDOVHCBMDRHNNW-UHFFFAOYSA-N 0.000 description 1
- UKQISBKFSDOYTL-UHFFFAOYSA-N CN1CC2C=CC=NC2CC1 Chemical compound CN1CC2C=CC=NC2CC1 UKQISBKFSDOYTL-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- NGCXHCGUQHIOLZ-UHFFFAOYSA-N C[n]1nccn1 Chemical compound C[n]1nccn1 NGCXHCGUQHIOLZ-UHFFFAOYSA-N 0.000 description 1
- XDHFUUVUHNOJEW-UHFFFAOYSA-N Cc([nH]1)cc2c1nccc2 Chemical compound Cc([nH]1)cc2c1nccc2 XDHFUUVUHNOJEW-UHFFFAOYSA-N 0.000 description 1
- FZESPVBONPPRAW-UHFFFAOYSA-N Cc([nH]1)nc2c1nccc2 Chemical compound Cc([nH]1)nc2c1nccc2 FZESPVBONPPRAW-UHFFFAOYSA-N 0.000 description 1
- XOKMRXSMOHCNIX-UHFFFAOYSA-N Cc(cc1)cc2c1NCCC2 Chemical compound Cc(cc1)cc2c1NCCC2 XOKMRXSMOHCNIX-UHFFFAOYSA-N 0.000 description 1
- SUOFFCWNMKSGNS-UHFFFAOYSA-N Cc(cc1)ccc1[I]=C Chemical compound Cc(cc1)ccc1[I]=C SUOFFCWNMKSGNS-UHFFFAOYSA-N 0.000 description 1
- PKZDPOGLGBWEGP-UHFFFAOYSA-N Cc1c[nH]c2c1cccn2 Chemical compound Cc1c[nH]c2c1cccn2 PKZDPOGLGBWEGP-UHFFFAOYSA-N 0.000 description 1
- ITXHYKBXKRUJNO-UHFFFAOYSA-N Cc1cc(cccn2)c2[s]1 Chemical compound Cc1cc(cccn2)c2[s]1 ITXHYKBXKRUJNO-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N Cc1ccc(C)[o]1 Chemical compound Cc1ccc(C)[o]1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- PPEJLOXOMBAXES-UHFFFAOYSA-N Cc1ccc(cncc2)c2c1 Chemical compound Cc1ccc(cncc2)c2c1 PPEJLOXOMBAXES-UHFFFAOYSA-N 0.000 description 1
- RWXZXCZBMQPOBF-UHFFFAOYSA-N Cc1ccc2nc[nH]c2c1 Chemical compound Cc1ccc2nc[nH]c2c1 RWXZXCZBMQPOBF-UHFFFAOYSA-N 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N Cc1ccc[o]1 Chemical compound Cc1ccc[o]1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- NSAUQTCATRWAJC-UHFFFAOYSA-N Cc1cnc(C)[o]1 Chemical compound Cc1cnc(C)[o]1 NSAUQTCATRWAJC-UHFFFAOYSA-N 0.000 description 1
- JLQCMGFETTYXSU-UHFFFAOYSA-N Cc1n[n](C)nc1 Chemical compound Cc1n[n](C)nc1 JLQCMGFETTYXSU-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ncccc1 Chemical compound Cc1ncccc1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- YVDWFZIVIIKYBQ-UHFFFAOYSA-N Cc1nnc(C)[o]1 Chemical compound Cc1nnc(C)[o]1 YVDWFZIVIIKYBQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534185P | 2017-07-18 | 2017-07-18 | |
| US62/534,185 | 2017-07-18 | ||
| PCT/US2018/042776 WO2019018583A1 (en) | 2017-07-18 | 2018-07-18 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200040764A true KR20200040764A (ko) | 2020-04-20 |
Family
ID=65014549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207004250A Withdrawn KR20200040764A (ko) | 2017-07-18 | 2018-07-18 | 1,8-나프티리디논 화합물 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10793561B2 (enExample) |
| EP (1) | EP3654982A4 (enExample) |
| JP (1) | JP2020527593A (enExample) |
| KR (1) | KR20200040764A (enExample) |
| CN (1) | CN111093666A (enExample) |
| AU (1) | AU2018302178A1 (enExample) |
| BR (1) | BR112020000962A2 (enExample) |
| CA (1) | CA3070073A1 (enExample) |
| IL (1) | IL272055A (enExample) |
| MX (1) | MX2020000693A (enExample) |
| SG (1) | SG11202000431PA (enExample) |
| WO (1) | WO2019018583A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| KR20200040764A (ko) * | 2017-07-18 | 2020-04-20 | 누베이션 바이오 인크. | 1,8-나프티리디논 화합물 및 그의 용도 |
| CN113613655A (zh) * | 2019-01-18 | 2021-11-05 | 诺维逊生物股份有限公司 | 化合物及其用途 |
| KR20210116550A (ko) | 2019-01-18 | 2021-09-27 | 누베이션 바이오 인크. | 아데노신 길항제로서의 헤테로시클릭 화합물 |
| AU2020207951A1 (en) * | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| CA3181538A1 (en) | 2020-05-05 | 2021-11-11 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| CN114507231B (zh) * | 2020-11-17 | 2025-06-03 | 南京再明医药有限公司 | 内酰胺类化合物及其制备方法 |
| JP2024504285A (ja) * | 2020-12-29 | 2024-01-31 | ティーエックスイノ バイオサイエンス インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途 |
| WO2022184116A1 (zh) * | 2021-03-05 | 2022-09-09 | 江苏先声药业有限公司 | 新型sos1抑制剂及其制备方法和应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| MXPA05009063A (es) | 2003-02-26 | 2005-12-12 | Sugen Inc | Compuestos de aminoheteroarilo como inhibidores de proteina cinasa. |
| JP2006521357A (ja) | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物 |
| RU2006118325A (ru) | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Производные пиразина и их фармацевтическое применение |
| CA2544191A1 (en) * | 2003-11-04 | 2005-05-26 | Merck & Co., Inc. | Substituted naphthyridinone derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| GB0800741D0 (en) | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| BRPI0910346A2 (pt) | 2008-03-31 | 2015-10-06 | Hoffmann La Roche | compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso |
| TW201102065A (en) * | 2009-05-29 | 2011-01-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| EP2531492B1 (en) | 2010-02-05 | 2016-04-13 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| KR101491938B1 (ko) * | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ｉｐ 수용체 효능제 헤테로시클릭 화합물 |
| CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| EP2718978B1 (en) | 2011-06-09 | 2018-05-16 | Novaled GmbH | Organic electronic device |
| UY34572A (es) | 2012-01-13 | 2013-09-02 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor ip |
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| JP6401773B2 (ja) | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| EP3521284B1 (en) | 2013-03-15 | 2020-12-02 | The Trustees of Columbia University in the City of New York | Pyrazine compounds as map kinase modulators and uses thereof |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| CN104341386A (zh) | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 |
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| ES2860695T3 (es) | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
| CA2940554A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
| ES2706888T3 (es) * | 2014-09-19 | 2019-04-01 | Forma Therapeutics Inc | Referencia cruzada a aplicaciones relacionadas |
| CA2967944C (en) | 2014-11-18 | 2020-11-17 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
| HK1245248B (en) | 2014-12-11 | 2020-05-15 | 恒翼生物医药(上海)股份有限公司 | Substituted heterocycles as bromodomain inhibitors |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| JP2018527293A (ja) | 2015-06-16 | 2018-09-20 | オリオン コーポレーション | ブロモドメイン阻害剤としてのスピロ［シクロブタン−１，３’−インドリン］−２’−オン誘導体 |
| SI3334431T1 (sl) | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| CN106478651B (zh) * | 2015-08-31 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| JP6863970B2 (ja) | 2015-09-21 | 2021-04-21 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環式化合物およびそれらの使用 |
| RU2018112312A (ru) | 2015-09-22 | 2019-10-23 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| MX391382B (es) | 2015-12-24 | 2025-03-21 | Corvus Pharmaceuticals Inc | Métodos de tratamiento de cáncer |
| AU2017290748A1 (en) | 2016-07-01 | 2019-01-17 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| NZ749275A (en) | 2016-07-01 | 2023-06-30 | G1 Therapeutics Inc | Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2018081863A1 (en) | 2016-11-04 | 2018-05-11 | University Of Wollongong | 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF |
| HRP20231157T1 (hr) | 2017-01-20 | 2024-01-05 | Arcus Biosciences, Inc. | Azolopirimidin za liječenje poremećaja povezanih s rakom |
| WO2018178338A1 (en) | 2017-03-30 | 2018-10-04 | Iteos Therapeutics | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| EP4112623A1 (en) | 2017-03-30 | 2023-01-04 | iTeos Belgium SA | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| CN107221611B (zh) | 2017-06-15 | 2019-02-05 | 江西冠能光电材料有限公司 | 一种稳定易加工有机半导体材料及其有机发光器件应用 |
| WO2019002606A1 (en) | 2017-06-30 | 2019-01-03 | Selvita S.A. | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| KR20200040764A (ko) * | 2017-07-18 | 2020-04-20 | 누베이션 바이오 인크. | 1,8-나프티리디논 화합물 및 그의 용도 |
| JP2021502342A (ja) | 2017-11-06 | 2021-01-28 | コーバス・ファーマシューティカルズ・インコーポレイテッド | 癌処置のためのアデノシン経路阻害剤 |
| CN109810111B (zh) | 2017-11-20 | 2023-10-27 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST |
| BR112020012527A2 (pt) | 2017-12-20 | 2020-11-24 | Betta Pharmaceuticals Co., Ltd | composto que funciona como inibidor de proteína com bromodomínio, e composição |
| CN111315747B (zh) | 2018-01-05 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 |
| US11427593B2 (en) | 2018-01-16 | 2022-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Bromodomain inhibitor compound and use thereof |
| WO2019148161A1 (en) | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| CN111511745B (zh) | 2018-02-06 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 吡唑并[1，5-a][1，3，5]三嗪-2-胺类衍生物、其制备方法及其应用 |
| JP2021512962A (ja) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | アデノシンａ２ａ受容体アンタゴニストによる腫瘍浸潤性リンパ球（ｔｉｌ）の拡大培養並びにｔｉｌ及びアデノシンａ２ａ受容体アンタゴニストの治療的組み合わせ |
| WO2019158070A1 (zh) | 2018-02-15 | 2019-08-22 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体拮抗剂 |
| US11479555B2 (en) | 2018-02-23 | 2022-10-25 | Newave Pharmaceutical Inc. | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase |
| PE20211001A1 (es) | 2018-02-27 | 2021-06-01 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
| AU2019227823B2 (en) | 2018-02-28 | 2024-12-12 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| KR102810102B1 (ko) | 2018-03-09 | 2025-05-21 | 리커리엄 아이피 홀딩스, 엘엘씨 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
-
2018
- 2018-07-18 KR KR1020207004250A patent/KR20200040764A/ko not_active Withdrawn
- 2018-07-18 JP JP2020503017A patent/JP2020527593A/ja active Pending
- 2018-07-18 BR BR112020000962-8A patent/BR112020000962A2/pt not_active Application Discontinuation
- 2018-07-18 AU AU2018302178A patent/AU2018302178A1/en not_active Abandoned
- 2018-07-18 WO PCT/US2018/042776 patent/WO2019018583A1/en not_active Ceased
- 2018-07-18 EP EP18835580.4A patent/EP3654982A4/en not_active Withdrawn
- 2018-07-18 US US16/039,301 patent/US10793561B2/en not_active Expired - Fee Related
- 2018-07-18 CN CN201880059414.8A patent/CN111093666A/zh active Pending
- 2018-07-18 MX MX2020000693A patent/MX2020000693A/es unknown
- 2018-07-18 SG SG11202000431PA patent/SG11202000431PA/en unknown
- 2018-07-18 CA CA3070073A patent/CA3070073A1/en active Pending
-
2020
- 2020-01-15 IL IL272055A patent/IL272055A/en unknown
-
2021
- 2021-12-13 US US17/644,052 patent/US20220220111A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020000962A2 (pt) | 2020-07-14 |
| US20220220111A1 (en) | 2022-07-14 |
| EP3654982A1 (en) | 2020-05-27 |
| JP2020527593A (ja) | 2020-09-10 |
| AU2018302178A1 (en) | 2020-02-13 |
| US10793561B2 (en) | 2020-10-06 |
| US20190023702A1 (en) | 2019-01-24 |
| SG11202000431PA (en) | 2020-02-27 |
| IL272055A (en) | 2020-03-31 |
| CN111093666A (zh) | 2020-05-01 |
| MX2020000693A (es) | 2020-07-29 |
| EP3654982A4 (en) | 2021-04-14 |
| WO2019018583A1 (en) | 2019-01-24 |
| CA3070073A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11028058B2 (en) | Heterocyclic compounds as adenosine antagonists | |
| US10793561B2 (en) | 1,8-naphthyridinone compounds and uses thereof | |
| US11306071B2 (en) | Heterocyclic compounds as adenosine antagonists | |
| KR20160049003A (ko) | 항증식성 화합물 | |
| US20220169648A1 (en) | 1,8-naphthyridinone compounds and uses thereof | |
| WO2020150675A1 (en) | Compounds and uses thereof | |
| JP2022517418A (ja) | アデノシンアンタゴニストとしてのヘテロ環式化合物 | |
| HK40058077A (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| HK1238630A1 (en) | Pyridone derivative having tetrahydropyranyl methyl group | |
| HK1238630B (en) | Pyridone derivative having tetrahydropyranyl methyl group |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |